Toolbox HIV - It's Over 9000!

G. F. Tchouwa; , S. Eymard-Duvernay; A. Cournil; et al. Elsevier; E Clinical Medecine (Published by the Lancet) (2018) C2

EClinicalMedicine 1 (2018) 21–27 https://doi.org/10.1016/j.eclinm.2018.06.005 2589-5370/© 2018 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). EClinicalMedicine: journal homepage: https://www.jo... more

Download (83)

View PDF (107)

WHO/HIVRESNET HIV drug resistance - laboratory operational framework

World Health Organization WHO (2020) C_WHO

The aim of the operational framework is to ensure 1) accurate collection, handling, shipment and storage of specimens collected in countries implementing HIV drug resistance surveillance; and 2) the availability of quality-assured HIV genotyping laboratory services producing comparable and reliable ... more

Download (61)

View PDF (99)

Modelling the impact of HIVDR : the cost of inaction

A. Phillips World Health Organization; UCL (2016) C_WHO

WHO Considering programmatic implications of rising levels of HIV drug resistance: finalizing the Global Action Plan Webinars 12 13 Dec 2016

Download (69)

View PDF (101)

HIV drug resistance SURVEYS: Tool for data entry

World Health Organization WHO (2017) C_WHO

HIV drug resistance , Users Manual December 2017

Download (63)

View PDF (91)

Global Action Plan on HIV Drug Resistance: Response to comments & modifications

World Health Organization (2016) C_WHO

12-13 December 2016 Global Action Plan on HIV Drug Resistance - Webinars 12-13 December 2016

Download (61)

View PDF (97)

AMR and HIV Drug resistance

L. Tayler World Health Organization; GHSA (2016) C_WHO

Download (88)

View PDF (102)

HIV drug resistance surveillance in countries scaling up pre-exposure prophylaxis

World Health Organization WHO (2020) C_WHO

WHO recommends that pre-exposure prophylaxis (PrEP) be offered as an additional prevention choice for HIV-negative individuals at substantial risk of HIV infection as part of combination prevention approaches. HIV drug resistance has been rarely reported among PrEP users who tested HIV positive i... more

Download (44)

View PDF (59)

Sentinel surveys of acquired HIV resistance to dolutegravir among people receiving dolutegravir-containing antiretroviral therapy

World Health Organization WHO (2022) C_WHO

WHO’s sentinel surveys of acquired HIV resistance to dolutegravir among people receiving dolutegravir-containing antiretroviral therapy is intended for easy and frequent implementation. Results from sentinel surveys provide insight into the prevalence and year-over-year trends of dolutegravir resi... more

Download (55)

View PDF (74)

Enquêtes par sites sentinelles sur la résistance acquise du VIH au dolutégravir chez les personnes sous traitement antirétroviral incluant ce médicament

World Health Organisation (WHO) (2023) C_WHO

Avec l’essor des traitements antirétroviraux (TAR) à base de dolutégravir (DTG) pour soigner les personnes vivant avec le VIH dans le monde, il est important d’estimer la vitesse à laquelle la résistance acquise au DTG apparaît dans les populations sous TAR. Bien que la résistance au DT... more

Download (42)

View PDF (80)

Estudios de vigilancia centinela de la resistencia adquirida por el VIH contra el dolutegravir en personas tratadas con este antirretrovírico en un esquema combinado